Reportedly, the Food and Drug Administration has halted the use of the Johnson & Johnson (JNJ) coronavirus vaccine, after reports of blood clots in six recipients were reported, pushing Johnson & Johnson’s stock down. All six cases occurred in women between the ages of 18 and 48 with symptoms like severe headache, abdominal pain, leg pain, or shortness of breath appearing within six to 13 days following vaccination.
The U.S. Centers for Disease Control and Prevention to hold a meeting this week to review the cases followed by a review by FDA. Until the review process is complete, the agencies recommended a pause in administering the J&J shot. So far 6.8 million Covid-19 vaccine doses have been administered in the U.S.
Blood clots are usually treated with a drug called heparin, which may “cause tremendous harm” in this case, informed the director of the Center for Biologics Evaluation and Research at the FDA, Peter Marks. Even though the vaccine is authorized in Europe, Johnson & Johnson informed that it has “made the decision to proactively delay the rollout” of its vaccine in Europe.
AstraZeneca’s vaccine has also been limited to people over the age of 30 in the U.K. after European regulators witnessed cases of blood clots with low blood platelets in recipients of that vaccine.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
